Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has raised GBP5.0 million (before expenses) by way of a placing to investors in the UK of 18,518,518 new ordinary shares of 0.1p each at an issue price of GBP0.27 per share ('Issue Price').

The UK Placing was significantly oversubscribed and brings new UK institutions into the Company's shareholder base.

The issue price of the Placing Shares represents a discount of approximately 32% to the closing middle market price of GBP0.395 per existing ordinary share on 24 July 2020, being the last Business Day before this announcement. The Placing Shares represent approximately 32% of the issued share capital of the Company as enlarged by the UK Placing.

The allotment of the Placing Shares is being made pursuant to existing authorities to allot shares and other relevant securities and to disapply pre-emption rights under section 551 of the Companies Act 2006, which the Directors were given at the Company's General Meeting held on 2 March 2020.

Turner Pope Investments (TPI) Limited ('Turner Pope') acted as sole bookrunner for the UK Placing.

Use of Proceeds

The proceeds of the UK Placing, net of fees and expenses, are expected to be approximately GBP4.6 million ('Net Proceeds'). The Net Proceeds will be used to: advance the Company's internal pipeline of Q-Sphera products through proof-of-concept and in vivo studies for potential out-licensing; develop Q-Sphera technology for unique application with biologic active pharmaceutical ingredients and general corporate purposes.

Taking into account available cash resources and the expected Net Proceeds, the Company expects to have sufficient cash resources to fund operations into the fourth quarter of 2021.

Further information on the Placing

The Company and Turner Pope entered into a placing agreement ('Placing Agreement'), pursuant to which Turner Pope agreed to use its reasonable endeavours to procure placees pursuant to the UK Placing.

The Placing Agreement contains certain warranties and indemnities by the Company in favour of Turner Pope. It also contains provisions entitling Turner Pope to terminate the Placing Agreement prior to Admission if, among other things, a breach of any of the warranties occurs or on the occurrence of an event fundamentally and adversely affecting the position of the Company.

Contact:

Craig Cook

Tel: +44 (0)1235 888300

Email: ir@midatechpharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire